

## ICMJE DISCLOSURE FORM

Date: March 15, 2023

Your Name: Hyungjin Kim

Manuscript Title: Tumor-associated prognostic factors extractable from chest CT scans in patients with lung cancer

Manuscript number (if known): TLCR-22-904

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Seoul National University Hospital Research Fund	No. 03-2022-2170
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>None</u>	
3	Royalties or licenses	<u>None</u>	
4	Consulting fees	RadiSen	Consultant

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	Medical IP	Stock and stock options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

**Please summarize the above conflict of interest in the following box:**

Hyungjin Kim received a research grant from Seoul National University Hospital Research Fund (No. 03-2022-2170); received consulting fees from RadiSen; and holds stock and stock options in Medical IP

**Please place an “X” next to the following statement to indicate your agreement:**

  x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: March 10, 2023

Your Name: Chang Min Park

Manuscript Title: Tumor-associated prognostic factors extractable from chest CT scans in patients with lung cancer

Manuscript number (if known): TLCR-22-904

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	√ None	
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ None	
3	Royalties or licenses	√ None	
4	Consulting fees	√ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	√ None	
6	Payment for expert testimony	√ None	
7	Support for attending meetings and/or travel	√ None	
8	Patents planned, issued or pending	√ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Seoul National University Hospital	Board member of big data review board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Korean Society of Artificial Intelligence in Medicine	
		Korean Society of Radiology	
		Korean Society of Thoracic Radiology	
11	Stock or stock options	Promedius	Stock
		Lunit	Stock option
		Coreline Soft	Stock option
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ None	
13	Other financial or non-financial interests	√ None	

**Please summarize the above conflict of interest in the following box:**

Dr. Chang Min Park serves as board member in Korean Society of Radiology, Korean Society of Thoracic Radiology, and Korean Society of Artificial Intelligence in Medicine and participates as a board member of Big Data Review Board of Seoul National University Hospital. He holds stock in Promedius and stock options in Lunit and Coreline Soft. He is an Editorial Board member of Translational Lung Cancer Research.

**Please place an “X” next to the following statement to indicate your agreement:**

**X  I certify that I have answered every question and have not altered the wording of any of the questions on this form.**